Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:

ABSTRACT Plasminogen activator inhibitor 1 (PAI-1) has been found to be a bad prognostic factor in a number of tumours but the reason has not been fully explained. The human prostate cancer
cell line PC-3 and the human promyelocytic leukaemia cell line HL-60 were used in this study to determine the effect of PAI-1 on spontaneous and induced apoptosis in culture. Apoptosis was
induced with camptothecin or etoposide. Addition of a stable variant of PAI-1 or wild-type PAI-1 to these cells resulted in a significant inhibition of apoptosis. In contrast, both the
latent form of PAI-1 and the stable variant of PAI-1 inactivated by a specific neutralizing monoclonal antibody, or the stable variant of PAI-1 in a complex with recombinant urokinase did
not inhibit apoptosis. This indicated that the inhibitory activity of PAI-1 was required for its anti-apoptotic effect but the urokinase-type plasminogen activator receptor was not involved.
These findings provide an explanation for the bad prognostic correlation of high PAI-1 levels in tumours. The anti-apoptotic effect was also found in non-tumoural cells including human
umbilical vein endothelial cells and the benign human breast epithelial cell line MCF-10A, suggesting that this is a novel physiologic function of PAI-1. © 2000 Cancer Research Campaign
SIMILAR CONTENT BEING VIEWED BY OTHERS PAI-1 IS A POTENTIAL TRANSCRIPTIONAL SILENCER THAT SUPPORTS BLADDER CANCER CELL ACTIVITY Article Open access 16 July 2022 ADAM10-CLEAVED EPHRIN-A5
CONTRIBUTES TO PROSTATE CANCER METASTASIS Article Open access 12 May 2022 THE BCL-2 INHIBITOR ABT-199/VENETOCLAX SYNERGIZES WITH PROTEASOME INHIBITION VIA TRANSACTIVATION OF THE MCL-1
ANTAGONIST NOXA Article Open access 20 April 2022 ARTICLE PDF CHANGE HISTORY * _ 16 NOVEMBER 2011 This paper was modified 12 months after initial publication to switch to Creative Commons
licence terms, as noted at publication _ REFERENCES * Alizadeh H, Ma D, Berman M, Bellingham D, Comerford SA, Gething MH, Sambrook JF and Niederkorn JY (1995) Tissue-type plasminogen
activator-induced invasion and metastasis of murine melanomas. _Curr Eye Res_ 14: 449–458 Article CAS Google Scholar * Andreasen PA, Kjoller L, Christensen L and Duffy MJ (1997) The
urokinase-type plasminogen activator system in cancer metastasis: a review. _Int J Cancer_ 72: 1–22 Article CAS Google Scholar * Bajou K, Noel A, Gerard RD, Masson V, Brunner N,
Holst-Hansen C, Skobe M, Fusening NE, Carmeliet P, Collen D and Foidart JM (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. _Nat Med_ 4:
923–928 Article CAS Google Scholar * Bashar H, Urano T, Pietrazek MH, Hata M, Suzuki K, Kawabe K, Takada Y and Takada A (1994) Plasminogen activators and plasminogen activator inhibitor
1 in urinary tract cancer. _Urol Int_ 52: 4–8 Article CAS Google Scholar * Cajot JF, Bamat J, Bergonzelli GE, Kruithof EKO, Medcalf RL and Testuz J (1990) Plasminogen activator inhibitor
type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. _Proc Natl Acad Sci USA_ 87: 6939–6943 Article CAS Google Scholar *
Casslen B, Bossmar T, Lecander I and Astedt B (1994) Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. _Eur J Cancer_ 30:
1302–1309 Article Google Scholar * Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. _Adv
Cancer Res_ 44: 139–266 Article CAS Google Scholar * Debrock S and Declerck PJ (1997) Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two
different mechanisms. _Biochim Biophys Acta_ 1337: 257–266 Article CAS Google Scholar * Deng G, Curriden SA, Wang S, Rosenberg S and Loskutoff DJ (1996) Is plasminogen activator
inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. _J Cell Biol_ 134: 1563–1571 Article CAS Google Scholar * Egelund R, Schousboe SL,
Sottrup-Jensen L, Rodenburg KW and Andreasen PA (1997) Type-1 plasminogen-activator inhibitor: conformational differences between latent, active, reactive-centre-cleaved and
plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. _Eur J Biochem_ 248: 775–785 Article CAS Google Scholar * Foekens JA, Schmitt M, van Putten WL, Peters HA,
Kramer MD, Janicke F and Klijn JG (1993) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. _J Clin Oncol_ 12: 1648–1658 Article Google Scholar * Gils A, Knockaert I
and Declerck PJ (1996) Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. _Biochem_ 35: 7474–7481 Article CAS
Google Scholar * Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K and Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its
inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. _Cancer Res_ 53: 2513–2521 CAS PubMed Google Scholar * Hofmann R, Lehmer A, Buresch M,
Hartung R and Ulm K (1996) Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. _Cancer_ 78: 487–492 Article CAS
Google Scholar * Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in
node-negative breast cancer. _Breast Cancer Res Treat_ 24: 195–208 Article CAS Google Scholar * Kanse SM, Kost C, Wilhelm OG, Andreasen PA and Preissner KT (1996) The urokinase receptor
is a major vitronectin binding protein on endothelial cells. _Exp Cell Res_ 224: 344–353 Article CAS Google Scholar * Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL,
Preissner KT, Ossowski L and Andreasen PA (1997) Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor
of plasminogen activation. _Exp Cell Res_ 232: 420–429 Article CAS Google Scholar * Kobayashi H, Fujishiro S and Terao T (1994) Impact of urokinase-type plasminogen activator and its
inhibitor type 1 on prognosis in cervical cancer of the uterus. _Cancer Res_ 54: 6539–6548 CAS PubMed Google Scholar * Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Janicke F and
Graeff H (1994) Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. _Gynecol Oncol_ 55: 401–409
Article CAS Google Scholar * Kwaan HC (1992) The plasminogen-plasmin system in malignancy. _Cancer Metast Rev_ 11: 291–311 Article CAS Google Scholar * Levenson AS, Kwaan HC, Svoboda
KM, Weiss IM, Sakurai S and Jordan VC (1998) Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen
receptor. _Br J Cancer_ 78: 88–95 Article CAS Google Scholar * Nekarda H, Siewert JR, Schmitt M and Ulm K (1994) Tumour-associated proteolytic factors uPA and PAI-1 and survival in
totally resected gastric cancer. _Lancet_ 343: 117 Article CAS Google Scholar * Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen HH, Dano K and Brunner N (1994) Urokinase and
plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. _Cancer Res_ 54: 120–123 CAS PubMed Google Scholar * Sancho E, Declerck PJ, Price NC, Kelly SM and Booth NA (1995)
Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms. _Biochemistry_ 34: 1064–1069 Article CAS Google Scholar * Sier CFM,
Vloedgraven HJM, Ganesh S, Griffion G, Quax PHA, Verheijen JH, Dooijewaard G, Welvaart K, van de Velde CJH, Lamers CBHW and Verspaget H (1994) Inactive urokinase and increased levels of
inhibitor type 1 in colorectal cancer liver metastasis. _Gastroenterology_ 10: 1449–1456 Article Google Scholar * Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S and Kwaan HC
(1995) Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver
in an athymic mouse model. _J Clin Invest_ 96: 2593–2600 Article CAS Google Scholar * Stefansson S and Lawrence DA (1996) The serpin PAI-1 inhibits cell migration by blocking integrin
alpha V beta 3 binding to vitronectin. _Nature_ 383: 441–443 Article CAS Google Scholar * Sugiura Y, Ma L, Sun B, Shimada H, Laug WE, Seeger RC and DeClerck Y (1999) The
plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis. _Cancer Res_ 59: 1327–1336 CAS PubMed Google Scholar * Verhamme I, Kvassman J, Day D,
Debrock S, Vleufels N, Declerck PJ and Shore JD (1999) Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. _J Biol Chem_ 274:
17511–17517 Article CAS Google Scholar * Vleugels N, Gils A, Mannaerts S, Knockaert I and Declerck PJ (1998) Evaluation of the mechanism of inactivation of plasminogen activator-1 by
monoclonal antibodies using a stable variant. _Fibrinolysis Proteolysis_ 12: 277–282 Article CAS Google Scholar * Waltz DA, Natkin LR, Fujita RM, Wei Y and Chapman HA (1997) Plasmin and
plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. _J Clin Invest_ 100: 58–67 Article CAS Google
Scholar * Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S and Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. _J Biol Chem_ 269:
32380–32388 CAS PubMed Google Scholar Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Division of Hematology/Oncology, Department of Medicine, Northwestern University
Medical School, Chicago, 60611, IL, USA H C Kwaan, J Wang & K Svoboda * Laboratory for Pharmaceutical Biology and Phytopharmacology, Faculty of Pharmaceutical Sciences, Katholieke
Universiteit Leuven, E. van Evenstraat 4, Leuven, B-3000, Belgium P J Declerck Authors * H C Kwaan View author publications You can also search for this author inPubMed Google Scholar * J
Wang View author publications You can also search for this author inPubMed Google Scholar * K Svoboda View author publications You can also search for this author inPubMed Google Scholar * P
J Declerck View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS From twelve months after its original publication, this work is
licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Kwaan, H., Wang, J., Svoboda, K. _et al._ Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of
apoptosis. _Br J Cancer_ 82, 1702–1708 (2000). https://doi.org/10.1054/bjoc.2000.1207 Download citation * Received: 09 September 1999 * Revised: 18 January 2000 * Accepted: 26 January 2000 *
Published: 21 April 2000 * Issue Date: 01 May 2000 * DOI: https://doi.org/10.1054/bjoc.2000.1207 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this
content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
KEYWORDS * apoptosis * plasminogen activator inhibitor 1 * uPA receptor